Heartseed (219A) · RiskRestated
Uncertainty in establishing manufacturing and supply chain capabilities
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of Delays in Establishing Pharmaceutical Manufacturing, Transportation and Sales Infrastructure and in SupplyA theme 5 companies write about · 5 as a headwind · 0 as a tailwind
2 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We are focusing on establishing manufacturing methods, including developing technologies for large-scale cell culture, with a view not only to our R&D activities but also to subsequent manufacturing, transportation and sales.」
While the Company is establishing manufacturing, transportation and sales systems, it continues to disclose risks including difficulties in building those systems, regulatory findings concerning data and management systems, and supply delays. - FY2024First statedAnnual report
「If it becomes difficult for any reason to establish manufacturing, transportation and sales systems, the supply of products for clinical trials or after approval could be delayed.」
The Company identifies the risk that delays in establishing manufacturing, transportation, sales and supply chain systems could affect clinical trials, supply and sales.